<DOC>
	<DOCNO>NCT01666184</DOCNO>
	<brief_summary>Study Design : Patients eligible ( 1 ) enrol TCOG 3207 ( 2 ) receive surgery biopsy pancreatic cancer ; ( 3 ) willing sign inform consent . The pancreatic tumor , tissue specimen blood sample treatment collect department pathology , surgery diagnostic medicine .</brief_summary>
	<brief_title>Biomarkers Study Pancreatic Cancer</brief_title>
	<detailed_description>We expect collect tissue sample 270 pancreatic cancer patient stage . Since enrollment criterion limit new patient , expect enroll 67 patient year . The patient enrollment complete 4 year . Clinical follow-up complete another one year . Data analysis correlation study may finish end 5th year study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Patients enrol TCOG 3207 study : A Randomized Phase III Study Adjuvant Gemcitabine versus Gemcitabine Plus Concurrent Chemoradiation Pancreatic Cancer Underwent Curative Intent ( R0 / R1 ) Resection . 2 . Patients eligible TCOG 3207 study receive surgery biopsy pancreatic cancer . 3 . Patients sign inform consent tissue specimen collection , accord regulation DOH .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Biomarkers study</keyword>
</DOC>